Mark V. Schaverien
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mark V. Schaverien has a total of 167 co-authors. Here are the top co-authors by number of shared publications:
- Joseph H. Dayan
Plastic and Reconstructive Surgery Service Department of Surgery Memorial Sloan Kettering Cancer Center New York New York USA
6 shared publications Benjamin D. Smith
Division of Radiation Oncology, Department of Breast Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston
5 shared publicationsCharles E. Butler
Department of Plastic Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX
5 shared publicationsJun Liu
Department of Plastic Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX
5 shared publicationsJesse C. M.D. Selber
From the Departments of Plastic Surgery and Thoracic and Cardiovascular Surgery and Rehabilitation Services, The University of Texas M. D. Anderson Cancer Center
4 shared publicationsJesse C. Selber
Department of Plastic Surgery, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX
4 shared publications
Latest Publications
- 14 May 2025
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
Comparison of Outcomes of Microsurgical Breast Reconstruction after Premastectomy and Postmastectomy Radiation Therapy
BACKGROUND: This study compared complication rates and outcomes between patients who underwent premastectomy radiation therapy (PreMRT) followed by mastectomy with microsurgical immediate breast reconstruction (IMBR) and patients who underwent mastectomy followed by postmastectomy RT (PMRT) then microsurgical delayed breast reconstruction (DBR). STUDY DESIGN: This is a secondary analysis of a randomized controlled trial (NCT02912312) that randomized patients with breast cancer to receive hypofractionated (40.05 Gy/15 fractions) or conventionally fractionated (50 Gy/25 fractions) regional nodal irradiation (RNI) between August 2018 and August 2022. Demographic, treatment, and outcomes data were collected. The primary outcome was the rate of autologous flap loss. Secondary outcomes included rates of other recipient-site complications. RESULTS: 144 patients were included: 41 underwent PreMRT with IMBR and 103 underwent PMRT with DBR, including 66 that had tissue expander (TE) placement at the time of mastectomy and 37 who underwent total mastectomy. The median time from mastectomy to DBR was 12.8 months (IQR, 9.7-16.3 months). There were no complete autologous flap losses in either group and rates of other recipient site complications were similar between the groups. Infection at the recipient site occurred in 20% (13/66) of patients in the PMRT group that underwent TE placement, and 9 (14%) required TE explantation because of complications. CONCLUSION: PreMRT with microvascular IMBR is associated with a similar complication rate to PMRT with microvascular DBR whilst avoiding complications relating to TE placement and a reduced time to achieve definitive breast reconstruction. A larger randomized clinical trial of PreMRT followed by mastectomy and IMBR is currently underway (NCT05774678).
- 14 May 2025
- Published by Wolters Kluwer Health in Journal of the American College of Surgeons
Comparison of Outcomes of Microsurgical Breast Reconstruction after Premastectomy and Postmastectomy Radiation Therapy
BACKGROUND: This study compared complication rates and outcomes between patients who underwent premastectomy radiation therapy (PreMRT) followed by mastectomy with microsurgical immediate breast reconstruction (IMBR) and patients who underwent mastectomy followed by postmastectomy RT (PMRT) then microsurgical delayed breast reconstruction (DBR). STUDY DESIGN: This is a secondary analysis of a randomized controlled trial (NCT02912312) that randomized patients with breast cancer to receive hypofractionated (40.05 Gy/15 fractions) or conventionally fractionated (50 Gy/25 fractions) regional nodal irradiation (RNI) between August 2018 and August 2022. Demographic, treatment, and outcomes data were collected. The primary outcome was the rate of autologous flap loss. Secondary outcomes included rates of other recipient-site complications. RESULTS: 144 patients were included: 41 underwent PreMRT with IMBR and 103 underwent PMRT with DBR, including 66 that had tissue expander (TE) placement at the time of mastectomy and 37 who underwent total mastectomy. The median time from mastectomy to DBR was 12.8 months (IQR, 9.7-16.3 months). There were no complete autologous flap losses in either group and rates of other recipient site complications were similar between the groups. Infection at the recipient site occurred in 20% (13/66) of patients in the PMRT group that underwent TE placement, and 9 (14%) required TE explantation because of complications. CONCLUSION: PreMRT with microvascular IMBR is associated with a similar complication rate to PMRT with microvascular DBR whilst avoiding complications relating to TE placement and a reduced time to achieve definitive breast reconstruction. A larger randomized clinical trial of PreMRT followed by mastectomy and IMBR is currently underway (NCT05774678).
- Top Cited PapersOpen Access
- 1 April 2024
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 7 (4) , e245217
Premastectomy Radiotherapy and Immediate Breast Reconstruction
Among patients with breast cancer who require mastectomy and radiotherapy (RT) and desire breast reconstruction, the sequencing of RT and reconstruction remains a clinical challenge.1-7 At present, breast reconstruction algorithms for patients requiring postmastectomy RT (PMRT) focus predominantly on avoiding delivery of radiation to the definitive reconstruction to avoid late toxic effects and consequent negative effects on patient satisfaction.1-7 These strategies include staged reconstruction with placement of a temporary tissue expander (TE) at the time of mastectomy,8 which is associated with high rates of cellulitis and explantation,9 which can delay RT10,11; alternatively, patients may undergo mastectomy without reconstruction. Delayed reconstruction is typically performed approximately 6 to 12 months after PMRT.9,12,13 Immediate breast reconstruction (IMBR) at the time of mastectomy has numerous advantages compared with delayed reconstruction, including performance of mastectomy and reconstruction in a single operation, reduced treatment costs, superior cosmetic results, and improved psychosocial patient-reported outcomes.13-15
- 1 April 2024
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 7 (4) , e245217
Top Cited PapersOpen AccessPremastectomy Radiotherapy and Immediate Breast Reconstruction
Among patients with breast cancer who require mastectomy and radiotherapy (RT) and desire breast reconstruction, the sequencing of RT and reconstruction remains a clinical challenge.1-7 At present, breast reconstruction algorithms for patients requiring postmastectomy RT (PMRT) focus predominantly on avoiding delivery of radiation to the definitive reconstruction to avoid late toxic effects and consequent negative effects on patient satisfaction.1-7 These strategies include staged reconstruction with placement of a temporary tissue expander (TE) at the time of mastectomy,8 which is associated with high rates of cellulitis and explantation,9 which can delay RT10,11; alternatively, patients may undergo mastectomy without reconstruction. Delayed reconstruction is typically performed approximately 6 to 12 months after PMRT.9,12,13 Immediate breast reconstruction (IMBR) at the time of mastectomy has numerous advantages compared with delayed reconstruction, including performance of mastectomy and reconstruction in a single operation, reduced treatment costs, superior cosmetic results, and improved psychosocial patient-reported outcomes.13-15
- Open Access
- 22 March 2024
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 205 (3) , 439-449
Development of a core set of outcome measures to be applied toward breast cancer-related lymphedema core outcome domains
Purpose: For breast cancer survivors (BCS) living with breast cancer-related lymphedema (BCRL), what outcome measures (OMs) are recommended to be used to measure standardized outcome domains to fully assess the burden of the disease and efficacy of interventions? An integral component of a standardized core outcome set (COS) are the OMs used to measure the COS. Methods: A supplemental online survey was linked to a Delphi study investigating a COS for BCRL. OMs were limited to a maximum of 10 options for each outcome domain (OD). There were 14 ODs corresponding to the International Classification of Functioning, Disability, and Health (ICF) framework and respondents rated the OMs with a Likert level of recommendation. The feasibility of the listed OMs was also investigated for most outpatient, inpatient, and research settings. Results: This study identified 27 standardized OMs with a few ODs having 2–3 highly recommended OMs for proper measurement. A few of the recommended OMs have limitations with reliability due to being semi-quantitative measures requiring the interpretation of the rater. Conclusion: Narrowing the choices of OMs to 27 highly recommended by BCRL experts may reduce selective reporting, inconsistency in clinical use, and variability of reporting across interdisciplinary healthcare fields which manage or research BCRL. There is a need for valid, reliable, and feasible OMs that measure tissue consistency. Measures of upper extremity activity and motor control need further research in the BCS with BCRL population.
- 22 March 2024
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 205 (3) , 439-449
Open AccessDevelopment of a core set of outcome measures to be applied toward breast cancer-related lymphedema core outcome domains
Purpose: For breast cancer survivors (BCS) living with breast cancer-related lymphedema (BCRL), what outcome measures (OMs) are recommended to be used to measure standardized outcome domains to fully assess the burden of the disease and efficacy of interventions? An integral component of a standardized core outcome set (COS) are the OMs used to measure the COS. Methods: A supplemental online survey was linked to a Delphi study investigating a COS for BCRL. OMs were limited to a maximum of 10 options for each outcome domain (OD). There were 14 ODs corresponding to the International Classification of Functioning, Disability, and Health (ICF) framework and respondents rated the OMs with a Likert level of recommendation. The feasibility of the listed OMs was also investigated for most outpatient, inpatient, and research settings. Results: This study identified 27 standardized OMs with a few ODs having 2–3 highly recommended OMs for proper measurement. A few of the recommended OMs have limitations with reliability due to being semi-quantitative measures requiring the interpretation of the rater. Conclusion: Narrowing the choices of OMs to 27 highly recommended by BCRL experts may reduce selective reporting, inconsistency in clinical use, and variability of reporting across interdisciplinary healthcare fields which manage or research BCRL. There is a need for valid, reliable, and feasible OMs that measure tissue consistency. Measures of upper extremity activity and motor control need further research in the BCS with BCRL population.
- Open Access
- 29 February 2024
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 205 (2) , 359-370
Development of a core outcome set for breast cancer-related lymphedema: a Delphi study
Purpose: For breast cancer survivors (BCS) living with breast cancer-related lymphedema (BCRL), what outcome domains (OD) should be measured to assess the burden of the disease and efficacy of interventions? A Core Outcome Set (COS) that promotes standardized measurement of outcomes within the constraints of time influenced by work environments is essential for patients and the multidisciplinary professionals that manage and research BCRL. Methods: Using Delphi methodology, a multidisciplinary group of BCRL experts (physical and occupational therapists, physicians, researchers, physical therapist assistants, nurses, and massage therapist) completed two waves of online surveys. BCRL expert respondents that completed the first survey (n = 78) had an average of 26.5 years in practice, whereas, respondents who completed the second survey (n = 33) had an average of 24.9 years. ODs were included in the COS when consensus thresholds, ranging from 70% to 80%, were met. Results: A total of 12 ODs made up the COS. Reaching a minimum consensus of 70%; volume, tissue consistency, pain, patient-reported upper quadrant function, patient-reported health-related quality of life, and upper extremity activity and motor control were recommended at different phases of the BCRL continuum in a time-constrained environment. Joint function, flexibility, strength, sensation, mobility and balance, and fatigue met an 80% consensus to be added when time and resources were not constrained. Conclusion: The COS developed in this study thoroughly captures the burden of BCRL. Using this COS may reduce selective reporting, inconsistency in clinical use, and variability of reporting across interdisciplinary healthcare fields, which manage or research BCRL.
- 29 February 2024
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 205 (2) , 359-370
Open AccessDevelopment of a core outcome set for breast cancer-related lymphedema: a Delphi study
Purpose: For breast cancer survivors (BCS) living with breast cancer-related lymphedema (BCRL), what outcome domains (OD) should be measured to assess the burden of the disease and efficacy of interventions? A Core Outcome Set (COS) that promotes standardized measurement of outcomes within the constraints of time influenced by work environments is essential for patients and the multidisciplinary professionals that manage and research BCRL. Methods: Using Delphi methodology, a multidisciplinary group of BCRL experts (physical and occupational therapists, physicians, researchers, physical therapist assistants, nurses, and massage therapist) completed two waves of online surveys. BCRL expert respondents that completed the first survey (n = 78) had an average of 26.5 years in practice, whereas, respondents who completed the second survey (n = 33) had an average of 24.9 years. ODs were included in the COS when consensus thresholds, ranging from 70% to 80%, were met. Results: A total of 12 ODs made up the COS. Reaching a minimum consensus of 70%; volume, tissue consistency, pain, patient-reported upper quadrant function, patient-reported health-related quality of life, and upper extremity activity and motor control were recommended at different phases of the BCRL continuum in a time-constrained environment. Joint function, flexibility, strength, sensation, mobility and balance, and fatigue met an 80% consensus to be added when time and resources were not constrained. Conclusion: The COS developed in this study thoroughly captures the burden of BCRL. Using this COS may reduce selective reporting, inconsistency in clinical use, and variability of reporting across interdisciplinary healthcare fields, which manage or research BCRL.
- Open Access
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
1819. The Impact of Vascularized Lymph Node Transplant in Reducing the Rate of Cellulitis in Patients with Breast Cancer–Related Lymphedema
Lymphedema following breast cancer surgery is a chronic and disabling complication that may lead to recurrent cellulitis. Innovative advances in treatment of breast cancer–related lymphedema have evolved beyond conservative management to include vascularized lymph node transplant (VLNT). Herein, we analyzed the impact of VLNT in reducing the rate of upper extremity cellulitis in breast cancer survivors. The charts of all patients who had breast cancer and mastectomy, whose course was complicated by upper extremity lymphedema, and who ultimately underwent VLNT at our comprehensive cancer center from 2017 to 2021 were reviewed. Patients who had at least one episode of cellulitis within the year prior to VLNT and were followed for 24 months were included. Thereafter, we reviewed patients’ demographics, cancer management, breast reconstructive procedures, VLNT surgeries, and infectious complications. The novel approach of VLNT in the management of breast cancer–related lymphedema is associated with significantly decreased recurrent cellulitis rates and should be considered as part of the infectious diseases treatment armamentarium. All Authors: No reported disclosures
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
Open Access1819. The Impact of Vascularized Lymph Node Transplant in Reducing the Rate of Cellulitis in Patients with Breast Cancer–Related Lymphedema
Lymphedema following breast cancer surgery is a chronic and disabling complication that may lead to recurrent cellulitis. Innovative advances in treatment of breast cancer–related lymphedema have evolved beyond conservative management to include vascularized lymph node transplant (VLNT). Herein, we analyzed the impact of VLNT in reducing the rate of upper extremity cellulitis in breast cancer survivors. The charts of all patients who had breast cancer and mastectomy, whose course was complicated by upper extremity lymphedema, and who ultimately underwent VLNT at our comprehensive cancer center from 2017 to 2021 were reviewed. Patients who had at least one episode of cellulitis within the year prior to VLNT and were followed for 24 months were included. Thereafter, we reviewed patients’ demographics, cancer management, breast reconstructive procedures, VLNT surgeries, and infectious complications. The novel approach of VLNT in the management of breast cancer–related lymphedema is associated with significantly decreased recurrent cellulitis rates and should be considered as part of the infectious diseases treatment armamentarium. All Authors: No reported disclosures
- Open Access
- 4 November 2022
- Published by KEAI Publishing in Bioactive Materials
- Vol. 22, 588-614
Harnessing the synergy of perfusable muscle flap matrix and adipose-derived stem cells for prevascularization and macrophage polarization to reconstruct volumetric muscle loss
Muscle flaps must have a strong vascular network to support a large tissue volume and ensure successful engraftment. We developed porcine stomach musculofascial flap matrix (PDSF) comprising extracellular matrix (ECM) and intact vasculature. PDSF had a dominant vascular pedicle, microcirculatory vessels, a nerve network, well-retained 3-dimensional (3D) nanofibrous ECM structures, and no allo- or xenoantigenicity. In-depth proteomic analysis demonstrated that PDSF was composed of core matrisome proteins (e.g., collagens, glycoproteins, proteoglycans, and ECM regulators) that, as shown by Gene Ontology term enrichment analysis, are functionally related to musculofascial biological processes. Moreover, PDSF−human adipose-derived stem cell (hASC) synergy not only induced monocytes towards IL-10−producing M2 macrophage polarization through the enhancement of hASCs' paracrine effect but also promoted the proliferation and interconnection of both human skeletal muscle myoblasts (HSMMs) and human umbilical vein endothelial cells (HUVECs) in static triculture conditions. Furthermore, PDSF was successfully prevascularized through a dynamic perfusion coculture of hASCs and HUVECs, which integrated with PDSF and induced the maturation of vascular networks in vitro. In a xenotransplantation model, PDSF demonstrated myoconductive and immunomodulatory properties associated with the predominance of M2 macrophages and regulatory T cells. In a volumetric muscle loss (VML) model, prevascularized PDSF augmented neovascularization and constructive remodeling, which was characterized by the predominant infiltration of M2 macrophages and significant musculofascial tissue formation. These results indicate that hASCs' integration with PDSF enhances the cells’ dual function in immunomodulation and angiogenesis. Owing in part to this PDSF-hASC synergy, our platform shows promise for vascularized muscle flap engineering for VML reconstruction.
- 4 November 2022
- Published by KEAI Publishing in Bioactive Materials
- Vol. 22, 588-614
Open AccessHarnessing the synergy of perfusable muscle flap matrix and adipose-derived stem cells for prevascularization and macrophage polarization to reconstruct volumetric muscle loss
Muscle flaps must have a strong vascular network to support a large tissue volume and ensure successful engraftment. We developed porcine stomach musculofascial flap matrix (PDSF) comprising extracellular matrix (ECM) and intact vasculature. PDSF had a dominant vascular pedicle, microcirculatory vessels, a nerve network, well-retained 3-dimensional (3D) nanofibrous ECM structures, and no allo- or xenoantigenicity. In-depth proteomic analysis demonstrated that PDSF was composed of core matrisome proteins (e.g., collagens, glycoproteins, proteoglycans, and ECM regulators) that, as shown by Gene Ontology term enrichment analysis, are functionally related to musculofascial biological processes. Moreover, PDSF−human adipose-derived stem cell (hASC) synergy not only induced monocytes towards IL-10−producing M2 macrophage polarization through the enhancement of hASCs' paracrine effect but also promoted the proliferation and interconnection of both human skeletal muscle myoblasts (HSMMs) and human umbilical vein endothelial cells (HUVECs) in static triculture conditions. Furthermore, PDSF was successfully prevascularized through a dynamic perfusion coculture of hASCs and HUVECs, which integrated with PDSF and induced the maturation of vascular networks in vitro. In a xenotransplantation model, PDSF demonstrated myoconductive and immunomodulatory properties associated with the predominance of M2 macrophages and regulatory T cells. In a volumetric muscle loss (VML) model, prevascularized PDSF augmented neovascularization and constructive remodeling, which was characterized by the predominant infiltration of M2 macrophages and significant musculofascial tissue formation. These results indicate that hASCs' integration with PDSF enhances the cells’ dual function in immunomodulation and angiogenesis. Owing in part to this PDSF-hASC synergy, our platform shows promise for vascularized muscle flap engineering for VML reconstruction.
- 4 August 2022
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery
- Vol. 150 (4) , 869e-879e
Single-Photon Emission Computed Tomographic Reverse Lymphatic Mapping for Groin Vascularized Lymph Node Transplant Planning
Background: Superficial inguinal (groin) vascularized lymph node transplantation is the most common option for the treatment of lymphedema, particularly in combination with free abdominal flap breast reconstruction. This study examines the utility of single-photon emission computed tomographic (SPECT/CT) lymphoscintigraphy for lower extremity reverse lymphatic mapping in presurgical planning for groin vascularized lymph node transplantation and appraises the physiologic lymphatic drainage to the superficial inguinal lymph nodes. Methods: All patients who underwent bilateral lower extremity SPECT/CT reverse lymphatic mapping over a 5-year period were included. Retrospective case note analysis was performed to collect demographic, surgical, and outcomes data. Results: The study included 84 patients; 56 of these subsequently underwent groin vascularized lymph node transplantation (58 flaps). Fifty-four of these flaps were combined with free abdominal flaps for breast reconstruction (55 flaps). Using SPECT/CT reverse lymphatic mapping investigation of 168 inguinal regions, drainage to at least one superficial inguinal region was visualized in 38.1 percent of patients; in 13.1 percent, drainage was visualized to both superficial inguinal regions. Using this information for presurgical planning, groin vascularized lymph node flap harvest was performed from the contralateral side in 57 of 58 cases (98.3 percent) using intraoperative gamma probe guidance, and no patient developed donor lower extremity lymphedema during follow-up (mean ± SD, 34.5 ± 15.4 months). Conclusions: The authors’ use of presurgical SPECT/CT reverse lymphatic mapping together with limited flap dissection and intraoperative gamma probe guidance resulted in no clinical cases of iatrogenic donor lower extremity lymphedema. The high incidence of drainage from the lower extremity to the superficial inguinal region mandates the use of reverse lymphatic mapping when performing groin vascularized lymph node transplantation. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, IV.
- 4 August 2022
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery
- Vol. 150 (4) , 869e-879e
Single-Photon Emission Computed Tomographic Reverse Lymphatic Mapping for Groin Vascularized Lymph Node Transplant Planning
Background: Superficial inguinal (groin) vascularized lymph node transplantation is the most common option for the treatment of lymphedema, particularly in combination with free abdominal flap breast reconstruction. This study examines the utility of single-photon emission computed tomographic (SPECT/CT) lymphoscintigraphy for lower extremity reverse lymphatic mapping in presurgical planning for groin vascularized lymph node transplantation and appraises the physiologic lymphatic drainage to the superficial inguinal lymph nodes. Methods: All patients who underwent bilateral lower extremity SPECT/CT reverse lymphatic mapping over a 5-year period were included. Retrospective case note analysis was performed to collect demographic, surgical, and outcomes data. Results: The study included 84 patients; 56 of these subsequently underwent groin vascularized lymph node transplantation (58 flaps). Fifty-four of these flaps were combined with free abdominal flaps for breast reconstruction (55 flaps). Using SPECT/CT reverse lymphatic mapping investigation of 168 inguinal regions, drainage to at least one superficial inguinal region was visualized in 38.1 percent of patients; in 13.1 percent, drainage was visualized to both superficial inguinal regions. Using this information for presurgical planning, groin vascularized lymph node flap harvest was performed from the contralateral side in 57 of 58 cases (98.3 percent) using intraoperative gamma probe guidance, and no patient developed donor lower extremity lymphedema during follow-up (mean ± SD, 34.5 ± 15.4 months). Conclusions: The authors’ use of presurgical SPECT/CT reverse lymphatic mapping together with limited flap dissection and intraoperative gamma probe guidance resulted in no clinical cases of iatrogenic donor lower extremity lymphedema. The high incidence of drainage from the lower extremity to the superficial inguinal region mandates the use of reverse lymphatic mapping when performing groin vascularized lymph node transplantation. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, IV.
- 10 May 2022
- Published by Springer Nature
- p. 47-52
Key Topic: Patient Selection and Evidence-Based Algorithmic Approach to Surgical Management of Lymphedema
- 10 May 2022
- Published by Springer Nature
- p. 47-52
Key Topic: Patient Selection and Evidence-Based Algorithmic Approach to Surgical Management of Lymphedema
- 10 May 2022
- Published by Springer Nature
- p. 193-197
Key Topic: Evaluating Outcomes of Lymphedema Surgery
- 10 May 2022
- Published by Springer Nature
- p. 193-197
Key Topic: Evaluating Outcomes of Lymphedema Surgery
- 10 May 2022
- Published by Springer Nature
- p. 29-38
Key Topic: Multimodal Evaluation of the Lymphedema Patient
- 10 May 2022
- Published by Springer Nature
- p. 29-38
Key Topic: Multimodal Evaluation of the Lymphedema Patient